Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.

Atsushi Horiike; Nobuyuki Yamamoto; Hisashi Tanaka; Noriko Yanagitani; Keita Kudo; Fumiyoshi Ohyanagi; Akira Ono; Tateaki Naito; Haruyasu Murakami; Takeshi Horai; Makoto Nishio

首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.

【24h】

Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.

机译：厄洛替尼对晚期非小细胞肺癌患者获得的吉非替尼耐药性的II期研究。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Erlotinib treatment after gefitinib failure may prolong the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors treatment.

机译：吉非替尼治疗失败后的厄洛替尼治疗可延长表皮生长因子受体酪氨酸激酶抑制剂的治疗效果。

著录项

来源
《Anticancer Research: International Journal of Cancer Research and Treatment》 |2014年第4期|共7页
作者
Atsushi Horiike; Nobuyuki Yamamoto; Hisashi Tanaka; Noriko Yanagitani; Keita Kudo; Fumiyoshi Ohyanagi; Akira Ono; Tateaki Naito; Haruyasu Murakami; Takeshi Horai; Makoto Nishio;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer. [J] . Atsushi Horiike, Nobuyuki Yamamoto, Hisashi Tanaka, Anticancer Research: International Journal of Cancer Research and Treatment . 2014,第4期

机译：Erlotinib的II期研究患有晚期非小细胞肺癌患者吉替尼的抗性。
2. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer. [J] . Atsushi Horiike, Nobuyuki Yamamoto, Hisashi Tanaka, Anticancer Research: International Journal of Cancer Research and Treatment . 2014,第4期

机译：厄洛替尼对晚期非小细胞肺癌患者获得的吉非替尼耐药性的II期研究。
3. A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib [J] . Lee Ji Yun, Sun Jong-Mu, Lim Sung Hee, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第9期

机译：Afatinib与Nimotuzumab联合治疗对吉非替尼或厄洛替尼具有耐药性的非小细胞肺癌患者的Ib / II期研究
4. Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer [C] . Pan Jingjing, Shi Meiqi, Feng Jifeng Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：吉非替尼耐药对晚期非小细胞肺癌患者的厄洛替尼治疗效果
5. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
6. Study of efficacy and safety of pulsatile administration of high‐dose gefitinib or erlotinib for advanced non‐small cell lung cancer patients with secondary drug resistance: A single center single arm phase II clinical trial [O] . Yanzhe Zhu, Yingying Du, Hu Liu, 2016

机译：大剂量吉非替尼或厄洛替尼脉冲治疗对继发耐药的晚期非小细胞肺癌患者的疗效和安全性研究：单中心单臂II期临床试验
7. P1-261: Resource utilization and therapy costs for patients with advanced stage IIIB/IV non-small cell lung cancer. Retrospective data from patients participating in the erlotinib phase IV study (TRUST) in Finland [O] . Mali Pekka, Karjalainen Eeva-Maija, Knuuttila Aija, 2007

机译：P1-261：晚期IIIB / IV期非小细胞肺癌患者的资源利用和治疗费用。来自芬兰埃罗替尼IV期研究（TRUST）的患者的回顾性数据

Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.

摘要

著录项

相似文献

相关主题

期刊订阅